Savolitinib Plus Osimertinib in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial
James Chih‐Hsin Yang(National Taiwan University Hospital), Jonathan W. Riess(University of California Davis Medical Center), Piyada Sitthideatphaiboon(King Chulalongkorn Memorial Hospital), Cheng‐Ta Yang(Shanghai Medical College of Fudan University), G.-C. Chang(Chung Shan Medical University Hospital), Teerapat Ungtrakul(The Royal College Of Anesthesiologists Of Thailand), Ryan J. Hartmaier(AstraZeneca (United States)), Alexander Gont(University of Ottawa), Jarin Chindaprasirt(Khon Kaen University), Kien Hung(Vietnam National Children's Hospital), Chaiyut Charoentum(Chiang Mai University), Matthew Haskins(AstraZeneca (United States)), I. Igwegbe(AstraZeneca (United States)), Wanning Xu(AstraZeneca (United States)), Ullas Batra(Rajiv Gandhi Cancer Institute and Research Centre), Pongwut Danchaivijitr(Siriraj Hospital), Juan Ignacio Hernández Morán(Universidad de Buenos Aires), Yuh‐Min Chen(National Yang Ming Chiao Tung University)
Cited by 3
Related Papers
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
|Journal of Clinical Oncology|2011|1.6k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k